🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are escalating around the world, with figures suggesting over 82 million new cases per year. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm its industry partner to see it through.

“This milestone marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

As per results published in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses a dual-drug approach. The study involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have expressed hope. Access to a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed crucial to alleviate the strain of the illness for individuals and to prevent the spread of untreatable gonorrhoea worldwide.